GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » Cash Flow from Investing

Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Cash Flow from Investing : $-627.5 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Amphastar Pharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Amphastar Pharmaceuticals spent $8.8 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $23.5 Mil on purchasing investments. It gained $47.5 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.0 Mil for other investing activities. In all, Amphastar Pharmaceuticals gained $15.2 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Amphastar Pharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for Amphastar Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Cash Flow from Investing Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.53 -36.42 -28.67 -32.78 -649.12

Amphastar Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.33 -508.58 -31.15 -103.05 15.24

Amphastar Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Amphastar Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Amphastar Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-627.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amphastar Pharmaceuticals  (NAS:AMPH) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Amphastar Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-8.8 Mil. It means Amphastar Pharmaceuticals spent $8.8 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Amphastar Pharmaceuticals's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.0 Mil. It means Amphastar Pharmaceuticals gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Amphastar Pharmaceuticals's purchase of business for the three months ended in Mar. 2024 was $0.0 Mil. It means Amphastar Pharmaceuticals spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Amphastar Pharmaceuticals's sale of business for the three months ended in Mar. 2024 was $0.0 Mil. It means Amphastar Pharmaceuticals gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Amphastar Pharmaceuticals's purchase of investment for the three months ended in Mar. 2024 was $-23.5 Mil. It means Amphastar Pharmaceuticals spent {stock_data.stock.currency_symbol}}23.5 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Amphastar Pharmaceuticals's sale of investment for the three months ended in Mar. 2024 was $47.5 Mil. It means Amphastar Pharmaceuticals gained $47.5 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Amphastar Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.0 Mil. It means Amphastar Pharmaceuticals paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Amphastar Pharmaceuticals's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.0 Mil. It means Amphastar Pharmaceuticals paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Amphastar Pharmaceuticals's cash from other investing activities for the three months ended in Mar. 2024 was $0.0 Mil. It means Amphastar Pharmaceuticals paid $0.0 Mil for other investing activities.


Amphastar Pharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Executives
Mary Z. Luo director, 10 percent owner, officer: COO and Chief Scientist 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Rong Zhou officer: EVP, Production C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Richard K Prins director
William J Peters officer: CFO, SVP & Treasurer C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi officer: SVP Corp Admin Center C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff director
Gayle Deflin director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst officer: EVP, QA & Regulatory Affairs 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee director 13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang director, 10 percent owner, officer: CEO & Chief Scientific Officer 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris director C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell director, officer: President 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc. 10 percent owner 13760 MAGNOLIA AVENUE, CHINO CA 91710